Wondering if earnings (4/26 for NYX i believe) might not be a time to expect a move? Then,
reaction to earnings can be hard to predict.

Didn't i here something about European insiders selling off some NYX.

i think the deal is so complex most of Wall St doesn't know what to think yet. Schwab
still has it as Not Rated. Most are in wait and see mode. Jim seems to spend a lot of time
talking to Thaine, and have a good handle on the situation. Give it time. Could very well
turn out nicely this year still. Based on the bet i've placed, i'm thinking the long run
looks great.

I think AMAT is a Q3 buy. I sold after the last conference call knowing that the company
would have a better idea where is was going after Q2. Things are looking up I think, but
I'll have to look closely and hear that strength is flowing into all the company's
components before I get back in.

I was surprised NYX hasn't taken off either. I hope this doesn't turn out to be another
BBY. :o(

Hey guys, The only reason NYX is down is because I got back into it LOL (it's been good
to me in the past).

Now that the Euronext deal closed, I am somewhat surprised that the stock hasn't had a
lift. I am reading the article on yahoo finance that said the possiblity of a
transatlantic exchange in the near future is not likely. i think Cramer was wrong to call
this the "stock of the year" becuase the synergies of the merger are not going to be
immediately in effect. The immediate benefits are cost savings, but without an integrated
exchange I don't know if NYX can compete with the other options exchanges in the near
future.

No. No tech for me until back to school and Christmas news starts hitting the airwaves.
Studying NYX. After the big push from Cramer, it's got a sell rating on the site? Nose
dived at the end today and has been trading in a range. Thoughts?

Apple is close to breaking below 90. Is anyone loading up monday morning?

Is that 32x multiple adjusted for today's earnings? I don't know, but I heard Merck upped
their forecast on fast money. Maybe there's something I need to look into. I don't know
what to think of DNA, not a hypergrowth company like Celgene so its not running up. My
area of expertise is not biotechs and I usually avoid reccommending them.

I did follow the DNA report. Results were good. Sales disappointed some. Even after the
post earnings fall off the stock still trades at 32x ttm earnings - toward the top of the
industry average.